PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
79.31%
Cash & equivalents growing 79.31% while GNPX's declined -20.09%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
79.31%
Below half of GNPX's -20.09%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
70.18%
Below half of GNPX's -19.25%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-6.11%
0.5-0.75x GNPX's -8.38%. Martin Whitman might see a risk of falling behind in asset investment or shifting strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.01%
Less than half of GNPX's 149.11%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-0.83%
Below half of GNPX's 69.23%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
67.39%
≥ 1.5x GNPX's 25.66%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-6.24%
Less than half of GNPX's 116.69%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-81.40%
Exceeding 1.5x GNPX's -24.19%. Michael Burry suspects ballooning short-term obligations vs. competitor.
-14.04%
Less than half of GNPX's 88.21%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.04%
Less than half of GNPX's 88.21%. David Dodd sees far fewer liability expansions relative to competitor.
36.75%
Above 1.5x GNPX's 1.43%. Michael Burry suspects heavy new equity expansion or dilution.
-4.17%
Similar yoy to GNPX's -4.45%. Walter Schloss sees parallel earnings retention vs. competitor.
-5.37%
Higher AOCI Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
105.08%
≥ 1.5x GNPX's 9.21%. David Dodd sees stronger capital base growth than competitor.
67.39%
≥ 1.5x GNPX's 25.66%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-79.31%
Less than half of GNPX's 20.09%. David Dodd sees better deleveraging or stronger cash buildup than competitor.